|
1
|
Juliusson G and Hough R: Leukemia. Prog
Tumor Res. 43:87–100. 2016. View Article : Google Scholar
|
|
2
|
Yamashita Y, Yuan J, Suetake I, Suzuki H,
Ishikawa Y, Choi YL, Ueno T, Soda M, Hamada T, Haruta H, et al:
Array-based genomic resequencing of human leukemia. Oncogene.
29:3723–3731. 2010. View Article : Google Scholar
|
|
3
|
Cammarata G, Augugliaro L, Salemi D,
Agueli C, La Rosa M, Dagnino L, Civiletto G, Messana F, Marfia A,
Bica MG, et al: Differential expression of specific microRNA and
their targets in acute myeloid leukemia. Am J Hematol. 85:331–339.
2010.
|
|
4
|
Akalin A, Garrett-Bakelman FE, Kormaksson
M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D,
Hess JL, et al: Base-pair resolution DNA methylation sequencing
reveals profoundly divergent epigenetic landscapes in acute myeloid
leukemia. PLoS Genet. 8:e10027812012. View Article : Google Scholar
|
|
5
|
Prada-Arismendy J, Arroyave JC and
Rothlisberger S: Molecular biomarkers in acute myeloid leukemia.
Blood Rev. 31:63–76. 2017. View Article : Google Scholar
|
|
6
|
Crump C, Sundquist J, Sieh W, Winkleby MA
and Sundquist K: Perinatal risk factors for acute myeloid leukemia.
Eur J Epidemiol. 30:1277–1285. 2015. View Article : Google Scholar
|
|
7
|
Fircanis S, Merriam P, Khan N and Castillo
JJ: The relation between cigarette smoking and risk of acute
myeloid leukemia: An updated meta-analysis of epidemiological
studies. Am J Hematol. 89:E125–E132. 2014. View Article : Google Scholar
|
|
8
|
Ferrara F and Schiffer CA: Acute myeloid
leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar
|
|
9
|
Kadia TM, Ravandi F, Cortes J and
Kantarjian H: New drugs in acute myeloid leukemia. Ann Oncol.
27:770–778. 2016. View Article : Google Scholar
|
|
10
|
Gomes BC, Rueff J and Rodrigues AS:
MicroRNAs and cancer drug resistance. Methods Mol Biol.
1395:137–162. 2016. View Article : Google Scholar
|
|
11
|
Bousquet M, Harris MH, Zhou B and Lodish
HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA.
107:21558–21563. 2010. View Article : Google Scholar
|
|
12
|
Fang L, Du WW, Yang W, Rutnam ZJ, Peng C,
Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, et al: miR-93
enhances angiogenesis and metastasis by targeting LATS2. Cell
Cycle. 11:4352–4365. 2012. View
Article : Google Scholar
|
|
13
|
Yeung ML, Yasunaga J, Bennasser Y, Dusetti
N, Harris D, Ahmad N, Matsuoka M and Jeang KT: Roles for microRNAs,
miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1
tumor suppressor in cell growth dysregulation by human T-cell
lymphotrophic virus 1. Cancer Res. 68:8976–8985. 2008. View Article : Google Scholar
|
|
14
|
Pan Y, Meng M, Zhang G, Han H and Zhou Q:
Oncogenic microRNAs in the genesis of leukemia and lymphoma. Curr
Pharm Des. 20:5260–5267. 2014. View Article : Google Scholar
|
|
15
|
Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W,
Ling Y, Wang R, Yang Y and Liu Y: Identification of circulating
microRNAs as potential biomarkers for detecting acute myeloid
leukemia. PLoS One. 8:e567182013. View Article : Google Scholar
|
|
16
|
Li L, Zhu L, Wang Y, Zhou D, Zhu J, Xie W
and Ye X: Profiling of microRNAs in AML cells following
overexpression or silencing of the VEGF gene. Oncol Lett.
13:105–110. 2017. View Article : Google Scholar
|
|
17
|
Chen L, Jiang M, Yuan W and Tang H:
Prognostic value of miR-93 overexpression in resectable gastric
adenocarcinomas. Acta Gastroenterol Belg. 75:22–27. 2012.
|
|
18
|
Fang L, Deng Z, Shatseva T, Yang J, Peng
C, Du WW, Yee AJ, Ang LC, He C, Shan SW and Yang BB: MicroRNA
miR-93 promotes tumor growth and angiogenesis by targeting
integrin-β8. Oncogene. 30:806–821. 2011. View Article : Google Scholar
|
|
19
|
Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X,
Zhou C and Jiao D: Identification of microRNA-93 as a functional
dysregulated miRNA in triple-negative breast cancer. Tumour Biol.
36:251–258. 2015. View Article : Google Scholar
|
|
20
|
Du L, Zhao Z, Ma X, Hsiao TH, Chen Y,
Young E, Suraokar M, Wistuba I, Minna JD and Pertsemlidis A:
miR-93-directed downregulation of DAB2 defines a novel oncogenic
pathway in lung cancer. Oncogene. 33:4307–4315. 2014. View Article : Google Scholar
|
|
21
|
Finkielstein CV and Capelluto DG:
Disabled-2: A modular scaffold protein with multifaceted functions
in signaling. Bioessays. 38(Suppl 1): S45–S55. 2016. View Article : Google Scholar
|
|
22
|
Tseng CP, Huang CL and Cheng JC: Serine 24
phosphorylation of Disabled-2 negatively regulates K562 cell
adhesion to fibrinogen. In: Proceedings of the The 95th Annual
Meeting of American Association for Cancer Research (AACR); AACR,
Orlando, FL. 2004
|
|
23
|
Wang B, Gu Q and Li J: DOC-2/DAB2
interactive protein regulates proliferation and mobility of
nasopharyngeal carcinoma cells by targeting PI3K/Akt pathway. Oncol
Rep. 38:317–324. 2017. View Article : Google Scholar
|
|
24
|
Martelli AM, Evangelisti C, Chiarini F,
Grimaldi C, Manzoli L and McCubrey JA: Targeting the PI3K/AKT/mTOR
signaling network in acute myelogenous leukemia. Expert Opin
Investig Drugs. 18:1333–1349. 2009. View Article : Google Scholar
|
|
25
|
Jiang L, Wang C, Lei F, Zhang L, Zhang X,
Liu A, Wu G, Zhu J and Song L: miR-93 promotes cell proliferation
in gliomas through activation of PI3K/Akt signaling pathway.
Oncotarget. 6:8286–8299. 2015. View Article : Google Scholar
|
|
26
|
Zhang Z and Shen T: Blood disease
diagnosis and efficacy standards. 3rd edition. Science Press;
Beijing: 2007
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar
|
|
29
|
Kozomara A, Birgaoanu M and
Griffiths-Jones S: MiRBase: From microRNA sequences to function.
Nucleic Acids Res. 47(D1): D155–D162. 2019. View Article : Google Scholar
|
|
30
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The http://microRNA.orgurisimplemicroRNA.org resource:
Targets and expression. Nucleic Acids Res. 36(Database Issue):
D149–D153. 2008. View Article : Google Scholar
|
|
31
|
Krek A, Grun D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar
|
|
32
|
Zhao J, Lu Q, Zhu J, Fu J and Chen YX:
Prognostic value of miR-96 in patients with acute myeloid leukemia.
Diagn Pathol. 9:762014. View Article : Google Scholar
|
|
33
|
Bernardoni R, Giordani G, Signorino E,
Monticelli S, Messa F, Pradotto M, Rosso V, Bracco E, Giangrande A,
Perini G, et al: A new BCR-ABL1 Drosophila model as a powerful tool
to elucidate the pathogenesis and progression of chronic myeloid
leukemia. Haematologica. 104:717–728. 2019. View Article : Google Scholar
|
|
34
|
Bose P, Vachhani P and Cortes JE:
Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat
Options Oncol. 18:172017. View Article : Google Scholar
|
|
35
|
Saygin C and Carraway HE: Emerging
therapies for acute myeloid leukemia. J Hematol Oncol. 10:932017.
View Article : Google Scholar
|
|
36
|
Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang
H, Hong M, Jiang T, Jiang Q, Lu J, et al: An oncogenic role of
miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by
targeting glucocorticoid receptor-α and cAMP/PKA pathways.
Leukemia. 26:769–777. 2012. View Article : Google Scholar
|
|
37
|
Deng ZQ, Qian J, Liu FQ, Lin J, Shao R,
Yin JY, Tang Q, Zhang M and He L: Expression level of miR-93 in
formalin-fixed paraffin-embedded tissues of breast cancer patients.
Genet Test Mol Biomarkers. 18:366–370. 2014. View Article : Google Scholar
|
|
38
|
Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang
L, Li J, Peng H, Cho WC, Wang E, et al: TGFβR2 is a major target of
miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer.
13:512014. View Article : Google Scholar
|
|
39
|
Meenhuis A, van Veelen PA, de Looper H,
van Boxtel N, van den Berge IJ, Sun SM, Taskesen E, Stern P, de Ru
AH, van Adrichem AJ, et al: miR-17/20/93/106 promote hematopoietic
cell expansion by targeting sequestosome 1-regulated pathways in
mice. Blood. 118:916–925. 2011. View Article : Google Scholar
|
|
40
|
Verboon LJ, Obulkasim A, de Rooij JD,
Katsman-Kuipers JE, Sonneveld E, Baruchel A, Trka J, Reinhardt D,
Pieters R, Cloos J, et al: MicroRNA-106b~25 cluster is upregulated
in relapsed MLL-rearranged pediatric acute myeloid leukemia.
Oncotarget. 7:48412–48422. 2016. View Article : Google Scholar
|
|
41
|
Pignataro D, Francia S, Zanetta F, Brenna
G, Brandini S, Olivieri A, Torroni A, Biamonti G and Montecucco A:
A missense MT-ND5 mutation in differentiated Parkinson Disease
cytoplasmic hybrid induces ROS-dependent DNA damage response
amplified by DROSHA. Sci Rep. 7:95282017. View Article : Google Scholar
|
|
42
|
Xu D, He XX, Chang Y, Sun SZ, Xu CR and
Lin JS: Downregulation of miR-93 expression reduces cell
proliferation and clonogenicity of HepG2 cells.
Hepatogastroenterology. 59:2367–2373. 2012.
|
|
43
|
Liang H, Wang F, Chu D, Zhang W, Liao Z,
Fu Z, Yan X, Zhu H, Guo W, Zhang Y, et al: miR-93 functions as an
oncomiR for the downregulation of PDCD4 in gastric carcinoma. Sci
Rep. 6:237722016. View Article : Google Scholar
|
|
44
|
Ruvolo PP, Jacamo R, McQueen T, Pan R,
Samudio I, Konopleva M, Kornblau SM, Garzon R, Croce CM and
Andreeff M: Suppression of Mir-93 may regulate anti-oxidant
metabolism in mesenchymal stromal cells derived from acute myeloid
leukemia patients. Blood. 120:23542012. View Article : Google Scholar
|
|
45
|
Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y,
Romero M, Leboeuf C, Janin A, Chen SJ, Wang L and Zhao WL:
MicroRNA187 overexpression is related to tumor progression and
determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Leukemia. 28:880–887. 2014. View Article : Google Scholar
|
|
46
|
Cheung KK, Mok SC, Rezaie P and Chan WY:
Dynamic expression of Dab2 in the mouse embryonic central nervous
system. BMC Dev Biol. 8:762008. View Article : Google Scholar
|
|
47
|
Park S, Chapuis N, Tamburini J, Bardet V,
Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C and
Bouscary D: Role of the PI3K/AKT and mTOR signaling pathways in
acute myeloid leukemia. Haematologica. 95:819–828. 2010. View Article : Google Scholar
|
|
48
|
Palacios F, Abreu C, Prieto D, Morande P,
Ruiz S, Fernandez-Calero T, Naya H, Libisch G, Robello C, Landoni
AI, et al: Activation of the PI3K/AKT pathway by microRNA-22
results in CLL B-cell proliferation. Leukemia. 29:115–125. 2015.
View Article : Google Scholar
|
